Palbociclib

BreastfeedingPediatric
  • TRADE NAME: Ibrance (Pfizer)
  • INDICATIONS: Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (in combination with letrozole)
  • CLASS: CDK4/6 inhibitor
  • HALF-LIFE: 29 hours

FDA APPROVAL DATE: 02/03/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bosentan, Carbamazepine, Clarithromycin, Efavirenz, Etravirine, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Modafinil, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Verapamil, Voriconazole

PREGNANCY CATEGORY: N/A
Can cause fetal harm

Our database has 47 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of palbociclib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 07/31/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top